Company Overview
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
Why Investors Should Care
Net profit has compounded at 20.1% per year over the last five years.
Revenue has grown at a 28.9% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.35.
Recent Developments
- Dec 2025 Revenue of $460.16M (+15.3% YoY); net profit $-175.54M.
- Trailing 12 Months Year-on-year growth — revenue -6.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 28.9%, profit CAGR 20.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 28.86% |
| 1 Year: | -6.50% |
Compounded Profit Growth
| 5 Years: | 20.13% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -50.38% |
| 6 Months: | +5.91% |
| 3 Months: | -15.57% |
| 1 Month: | -4.60% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)39.99 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 28.9% over 5 years.
- Profit CAGR of 20.1% over 5 years.
CONS
- Trading 53.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ZLAB Zai Lab Limited | 18.27 | -10.75 | $2.06B | 0.00% | -22.91% | -24.19% | 28.86% | 20.13% |
| 2 | LLY Eli Lilly and Company SPX | 1,148.84 | 40.85 | $1.02T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 256.35 | 29.74 | $617.09B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 250.94 | 122.41 | $443.36B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 130.20 | 36.68 | $321.57B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 169.64 | 26.30 | $263.09B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 574.30 | 31.54 | $213.42B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 385.16 | 26.78 | $207.87B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 106.49M | 109.98M | 116.09M | 127.60M | 99.61M |
| Cost of Revenue | - | 38.65M | 43.22M | 46.88M | 62.33M | 38.34M |
| Gross Profit | - | 67.84M | 66.76M | 69.21M | 65.27M | 61.28M |
| Operating Expenses | - | 124.14M | 117.80M | 117.18M | 133.53M | 130.56M |
| Operating Income | - | -56.30M | -51.05M | -47.97M | -68.26M | -69.28M |
| EBITDA | - | -43.79M | -35.73M | -30.66M | -48.06M | -43.99M |
| Interest Expense | - | 1.19M | 1.26M | 1.40M | 1.36M | 1.64M |
| Pretax Income | - | -48.44M | -40.73M | -35.96M | -53.34M | -49.58M |
| Tax Provision | - | 0 | 0 | 0 | -2.93M | 1.44M |
| Net Income | - | -48.44M | -40.73M | -35.96M | -50.41M | -51.02M |
| Diluted EPS | - | -0.40 | -0.40 | -0.30 | -0.50 | -0.50 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 215.04M | 266.72M | 398.99M | 460.16M |
| Cost of Revenue | - | 74.02M | 95.82M | 147.86M | 191.08M |
| Gross Profit | - | 141.02M | 170.90M | 251.13M | 269.07M |
| Operating Expenses | - | 533.91M | 545.04M | 525.08M | 492.65M |
| Operating Income | - | -392.89M | -374.14M | -273.95M | -223.57M |
| EBITDA | - | -434.84M | -325.59M | -242.99M | -158.25M |
| Interest Expense | - | 0 | 0 | 2.25M | 5.21M |
| Pretax Income | - | -443.06M | -334.62M | -257.10M | -178.46M |
| Tax Provision | - | 0 | 0 | 0 | -2.93M |
| Net Income | - | -443.29M | -334.62M | -257.10M | -175.54M |
| Diluted EPS | - | -4.60 | -3.50 | -2.60 | -1.60 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 1.22B | 1.04B | 1.19B | 1.17B |
| Current Assets | - | 1.12B | 939.61M | 1.05B | 1.02B |
| Cash & Equivalents | - | 1.01B | 790.15M | 449.67M | 679.57M |
| Inventory | - | 31.62M | 44.83M | 39.88M | 74.75M |
| Receivables | - | 39.96M | 59.20M | 85.18M | 106.12M |
| Total Liabilities | - | 174.54M | 240.18M | 344.86M | 456.88M |
| Current Liabilities | - | 139.84M | 203.07M | 299.38M | 416.17M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 20.39M | 15.15M | 153.47M | 224.26M |
| Total Equity | - | 1.05B | 796.12M | 840.90M | 715.50M |
| Shares Outstanding | - | 962.46M | 977.15M | 1.08B | 1.11B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -367.64M | -198.18M | -214.87M | -150.79M |
| Investing Cash Flow | - | 420.02M | -10.78M | -375.19M | 307.87M |
| Financing Cash Flow | - | -1.73M | -6.43M | 349.89M | 72.35M |
| Capital Expenditure | - | -24.98M | -8.49M | -61.52M | -13.42M |
| Free Cash Flow | - | -392.63M | -206.67M | -276.39M | -164.21M |
| Net Change in Cash | - | 50.64M | -215.39M | -240.17M | 229.43M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 65.6% | 64.1% | 62.9% | 58.5% |
| Operating Margin % | - | -182.7% | -140.3% | -68.7% | -48.6% |
| Net Margin % | - | -206.1% | -125.5% | -64.4% | -38.1% |
| ROE % | - | -42.4% | -42.0% | -30.6% | -24.5% |
| ROCE % | - | -36.4% | -44.9% | -30.9% | -29.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RTW Investments LP | 5.78% | 6.57M | $120.11M |
| 2 | RA Capital Management, L.P. | 5.02% | 5.71M | $104.27M |
| 3 | Frazier Life Sciences Management, L.P. | 1.67% | 1.90M | $34.76M |
| 4 | Citadel Advisors Llc | 1.48% | 1.69M | $30.85M |
| 5 | BAMCO Inc. | 1.46% | 1.66M | $30.30M |
| 6 | Adar1 Capital Management, LLC | 1.25% | 1.43M | $26.04M |
| 7 | FMR, LLC | 1.11% | 1.26M | $23.06M |
| 8 | Blackrock Inc. | 0.76% | 865.15K | $15.81M |
| 9 | Rock Springs Capital Management, LP | 0.72% | 814.71K | $14.88M |
| 10 | C WorldWide Group Holding A/S | 0.45% | 510.00K | $9.32M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ZLAB
ZLAB — Frequently Asked Questions
What is the current share price of Zai Lab Limited (ZLAB)?
As of 2026-08-02 19:16 PDT, Zai Lab Limited (ZLAB) trades at $18.27 on NasdaqGM. Its 52-week range is $16.30 to $39.51.
What is the market capitalisation of ZLAB?
Zai Lab Limited (ZLAB) has a market capitalisation of $2.06B on NasdaqGM.
What is the P/E ratio of ZLAB?
ZLAB trades at a trailing price-to-earnings (P/E) ratio of -10.75. The industry average P/E is 27.41. Its price-to-book (P/B) ratio is 3.06.
What is the return on equity (ROE) of ZLAB?
ZLAB has a return on equity (ROE) of -24.19%. Its return on capital employed (ROCE) is -22.91%.
Is ZLAB a good stock to buy?
This page provides a data-driven analysis of Zai Lab Limited (ZLAB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.